What is the new safety concern with Ozempic and Mounjaro?

Australia's regulator has warned that GLP-1 agonists like Ozempic and Mounjaro may be linked to an increased risk of suicidal thoughts and self-harming behavior.

Are there any other warnings for Mounjaro users?

Yes, Mounjaro users are now advised to use non-oral contraception due to potential interactions that could decrease the effectiveness of birth control pills.

What should I do if I experience mood changes while on GLP-1 drugs?

If you experience new or worsening depression or suicidal thoughts, tell your health professional immediately.

Home / Health / Weight Loss Drugs Linked to Harmful Thoughts

Weight Loss Drugs Linked to Harmful Thoughts

1 Dec

•

Summary

GLP-1 agonists like Ozempic may increase self-harming thoughts.
Australia's regulator issued a safety warning on Monday.
Contraception advice updated for Mounjaro users.

Weight Loss Drugs Linked to Harmful Thoughts

Australia's medicine regulator has issued a significant safety warning concerning GLP-1 receptor agonists, commonly used for weight loss, including popular drugs like Ozempic and Mounjaro. Recent reviews revealed a concerning number of reports linking these medications to a higher risk of suicidal ideation and self-harming behaviors. This has prompted an update to the drug warnings and advice for patients and healthcare professionals.

The Therapeutic Goods Administration (TGA) reported 85 adverse event notifications associated with GLP-1 receptor agonists, with a substantial portion indicating suicidal thoughts or depression. While initial assessments suggested insufficient evidence, further investigation highlighted a potential connection between weight loss itself and these mental health concerns, alongside the complex interplay with chronic endocrine disorders treated by these drugs.

In addition to mental health risks, the TGA also updated warnings for Mounjaro regarding its potential impact on oral contraception effectiveness. Patients are now advised to use alternative non-oral contraception methods during initial treatment and after dose adjustments. The regulator emphasizes that individuals experiencing new or worsening depression or suicidal thoughts should immediately consult their healthcare provider.